Eli Lilly & Co Data Affirm Benefit Of Alimta ®
Results from recent studies confirm that Alimta®, Eli Lilly’s FDA-approved drug for mesothelioma, does have clinical efficacy for the treatment of malignant pleural mesothelioma. The studies looked at Alimta given as a single agent and in combination with a platinum agent, such as cisplatin or carboplatin—which is the standard chemotherapy treatment for mesothelioma. The one-year survival rates were similar between single agent therapy and combination therapy, with Alimta alone showing a 58.6% one-year rate and then Alimta + cisplatin with a 63.1% rate and Alimta + carboplatin with a 64.0% rate. When looking at overall response rate, Alimta plus the platinum agents (26.3% for Alimta+cisplatin and 21.7% for Alimta+ carboplatin) showed a higher response than ALIMTA alone (10.5%).
The findings were presented at the 12th World Conference on Lung Cancer.